Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: Results of a double-blind, randomized, placebo-controlled trial

Journal of Clinical Psychiatry

Volumn 69, Issue 1, 2008, Pages 87-94

  Ravindran, Arun V ^a   Kennedy, Sidney H ^a   O'Donovan, M Claire ^b   Fallu, Angelo ^c   Camacho, Fernando ^d   Binder, Carin E ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c Clinique Woodward   (Canada)

^d DAMOS Inc   (Canada)

^e Janssen Ortho Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; METHYLPHENIDATE; MIRTAZAPINE; PAROXETINE; PLACEBO; SERTRALINE; VENLAFAXINE;

ABDOMINAL CRAMP; ADULT; AGED; ANOREXIA; ANXIETY DISORDER; APATHY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RELEASE; ELECTROCARDIOGRAM; FATIGUE; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIGRAINE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; MULTIDIMENSIONAL SCALING; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SWEATING; TREATMENT DURATION; TREATMENT FAILURE; XEROSTOMIA;

EID: 39549119969     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0112     Document Type: Article

References (31)

1. Kennedy SH, Lam RW. Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. Bipolar Disord 2003;5(suppl 2):36-47
2. Jacobson A. The use of Ritalin in psychotherapy of depressions of the aged. Psychiatr Q 1958;32:474-483
3. Concerta [product monograph]. Fort Washington, Pa: McNeil Pediatrics; July 26, 2005
4. Gwirtsman HE, Szuba MP, Toren L, et al. The antidepressant response to tricyclics in major depressives is accelerated with adjunctive use of methylphenidate. Psychopharmacol Bull 1994;30:157-164
5. Stoll AL, Pillay SS, Diamond L, et al. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry 1996;57:72-76
6. Masand PS, Anand VS, Tanquary JF. Psychostimulant augmentation of second generation antidepressants: a case series. Depress Anxiety 1998;7:89-91
7. Lavretsy H, Kim M-D, Kumar A, et al. Methylphenidate-enhanced antidepressant response to citalopram for accelerated response in the elderly: an open trial. J Clin Psychiatry 2003;64:1410-1414
8. Lavretsky H, Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geriatr Psychiatry 2001;9:298-303
9. Lavretsky H, Park S, Siddarth P, et al. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. Am J Geriatr Psychiatry 2006;14:181-185
10. Masand PS, Peindl K, Hooper-Wood C, et al. A randomized, double-blind, placebo-controlled, flexible dose trial of augmentation with OROS methylphenidate in treatment-resistant depression. Presented at the 46th annual meeting of the New Clinical Drug Evaluation Unit [poster 62]; June 13, 2006; Boca Raton, Fla
11. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The validity of the Mini-International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry 1997;12:232-241
12. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
13. Guy W, Bonato RR, eds. CGI: Clinical Global Impressions. In: Manual for the ECDEU Assessment Battery 2, Revised Edition. Chevy Chase, Md: National Institute of Mental Health; 1970:12.1-12.6
14. Williams JBW, Link MJ, Rosenthal NE, et al. Structured interview guide for the Hamilton Depression Rating Scale, seasonal affective disorders version (SIGH-SAD). New York, NY: New York State Psychiatric Institute; 1992
15. Kennedy SH, Fulton K, Bagby RM, et al. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry 2006;51:234-242
16. Bormann J, Shively M, Smith TL, et al. Measurement of fatigue in HIV-positive adults: reliability and validity of the global fatigue index. J Assoc Nurses AIDS Care 2001;12:75-83
17. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatr Res 1991;38:143-162
18. Miller FE. Strategies for the rapid treatment of depression. Hum Psychopharmacol 2001;16:125-132
19. Naor S, Talmon Y, Guy N. Combined tricyclic antidepressants and Ritalin in elderly depressives. Harefuah 1992;123:251-252
20. El-Mallakh RS. An open study of methylphenidate in bipolar depression. Bipolar Disord 2000;2:56-59
21. Carlson PJ, Merlock MC, Suppes T. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord 2004;6:416-420
22. George MS, Lydiard RB. Speed of onset of action of the newer antidepressants: fluoxetine and bupropion. Int Clin Psychopharmacol 1991;6:209-217
23. Bech P. Acute therapy of depression. J Clin Psychiatry 1993;54(suppl):18-27
24. Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol 1999;14:329-337
25. Tylee A, Gastpar M, Lepine JP, et al. Identification of depressed patient types in the community and their treatment needs: findings from the DEPRES II (Depression Research in European Society II) survey. DEPRES Steering Committee. Int Clin Psychopharmacol 1999;14:153-165
26. Maurice-Tison S, Verdoux H, Gay B, et al. How to improve recognition and diagnosis of depressive syndromes using international diagnostic criteria. Br J Gen Pract 1998;48:1245-1246
27. Kapur S, Mann JJ. Role of the dopaminergic system in depression. Biol Psychiatry 1992;32:1-17
28. DeBattista C, Doghramji K, Menza MA, et al. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003;64:1057-1064
29. Schwartz TL, Azhar N, Cole K et al. An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. J Clin Psychiatry 2004;65:1223-1227
30. Roth BL, Meltzer HY. The role of serotonin in schizophrenia. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven; 1995:1215-1227
31. Pies RW, ed. Chapter 2: Antidepressants. In: Handbook of Essential Pharmacology, 2nd edition. Washington, DC: American Psychiatric Publishing Inc; 2005:19-138